It determined the VAF of ovarian cancer‐related mutations KRAS‐G12R, NRAS‐G12C, and BRAF‐V600E in both tissue and blood samples (n = 77), discriminating cancer patients and healthy individuals with significant difference (p < 0.001). This evidence concerns the gene NRAS and cancer.